CEL-SCI Multikine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Seven of 10 patients with advanced head and neck cancer who received six 1600 IU injections of the leukocyte interleukin had tumor reductions before surgery or radiation during an 18-day drug treatment period, the company reported. Ten patients each were assigned to one of three dosage groups: 800 IU, 1600 IU, and 3200 IU, given in six injections over 18 days. Six of 10 patients treated with the lowest dose and three of 10 treated with the highest dose experienced tumor reductions. Two patients in the 800 IU group and three patients in the 1600 IU group had a greater than 50% reduction in tumor size. The company reported no significant toxicity. Phase III studies are expected to begin in 2001